UK markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.43+0.47 (+3.14%)
At close: 04:00PM EDT
15.72 +0.29 (+1.88%)
After hours: 06:49PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.20B
Enterprise value 1.22B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.41
Price/book (mrq)2.13
Enterprise value/revenue 3.68
Enterprise value/EBITDA -6.76

Trading information

Stock price history

Beta (5Y monthly) 1.33
52-week change 3-40.19%
S&P500 52-week change 322.36%
52-week high 333.31
52-week low 314.56
50-day moving average 318.96
200-day moving average 320.71

Share statistics

Avg vol (3-month) 31.25M
Avg vol (10-day) 31.35M
Shares outstanding 5142.54M
Implied shares outstanding 6142.54M
Float 8120.17M
% held by insiders 113.77%
% held by institutions 179.49%
Shares short (15 Apr 2024) 49.58M
Short ratio (15 Apr 2024) 49.3
Short % of float (15 Apr 2024) 47.87%
Short % of shares outstanding (15 Apr 2024) 46.72%
Shares short (prior month 15 Mar 2024) 48.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -43.94%
Operating margin (ttm)-59.51%

Management effectiveness

Return on assets (ttm)-9.40%
Return on equity (ttm)-14.01%

Income statement

Revenue (ttm)330.53M
Revenue per share (ttm)2.41
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -187.87M
Net income avi to common (ttm)-145.22M
Diluted EPS (ttm)-1.06
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.03B
Total cash per share (mrq)7.43
Total debt (mrq)52.24M
Total debt/equity (mrq)5.07%
Current ratio (mrq)13.65
Book value per share (mrq)7.45

Cash flow statement

Operating cash flow (ttm)-357.99M
Levered free cash flow (ttm)-298.35M